Qinjin Fan, PhD, on Equitable Lung Cancer Care and Mortgage Discrimination
2022 ASCO Quality Care Symposium
Qinjin Fan, PhD, of the American Cancer Society, explores the question of how mortgage discrimination is linked to lower rates of guideline-concordant care for patients with non–small cell lung cancer. This study highlights the critical need to understand the pathways through which mortgage denials may negatively affect the receipt of equitable care (Abstract 3).
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
As we know that lung cancer is the second most common cancer diagnosed and the leading cause of cancer death in the United States. And the housing insecurity is a important social determinant of health that can influence and be influenced by cancer diagnosis and care across the continuum. So, there are multiple pathways through which housing insecurity can affect cancer patients, and one of them is housing discrimination.
In this study, we look at the area level mortgage denial rate as a marker for the sustained lending discrimination and the neighborhood disinvestment. And we then investigated the association between residing in areas with high mortgage denial rates and the result of quality cancer care and outcome among individuals diagnosed with non-small cell lung cancer.
To investigate that, we selected individuals diagnosed with non-small cell lung cancer between 2014 to 2019, from the National Cancer database. So, the NCDP is a nationwide hospital-based cancer registry. It captures about 70% newly diagnosed cases in the US and it is co-sponsored by the American College of Surgeons at American Cancer Society, and it collects detailed and standardized information on patients tumor treatment and outcomes in all states.
The mortgage data were collected from the Home Mortgage Disclosure Act database, which is publicly available and has information on mortgage lending practices. So, we estimated the mortgage denial rate as the proportion of denied home loans, to the total of completed home loans. And we categorize them into quantiles, where level one is the lowest, and the level four is the highest. And in this study, we have multiple outcomes of interest.
First, the result of guideline concordant care, including surgery or radiation, lymph nodes evaluation, new adjuvant chemo radiation and adjuvant chemotherapy. So, the treatment eligibility and the result of guideline concordant care were defined based on the National Comprehensive Cancer Network guidelines.
Our results showed that individuals residing in areas with high mortgage denial rates were less likely to receive guideline concordant care for non-small cell lung cancer. And this association was consistent across all treatment sub-groups, with an exception for new adjuvant chemo radiation.
Similarly, we found that individual residing in areas with high mortgage denial rates had worse access to timely chemotherapy and had worse overall survival.
Our findings highlight the critical needs to understand the pathways, through which institutional practices leading to barriers in access to resources such as mortgage denials, can negatively affect access to equitable cancer care and outcomes.
Regina Barragán-Carrillo, MD, of Mexico’s National Institute of Medical Sciences and Nutrition Salvador Zubirán, discusses her findings showing that currently, physicians have limited knowledge about breast cancer screening in transgender patients. Were this topic addressed with widespread information, it could possibly reduce the health-care inequalities faced by this diverse group of patients (Abstract 71).
Justin M. Barnes, MD, of the Washington University School of Medicine, discusses the ways in which Medicaid expansion under the Affordable Care Act seems to affect distant diagnoses and cancer deaths per year, the differences in the impact of expansion between Black and White patients in the United States, and why insurance alone appears to be insufficient to overcome structural barriers to care for some populations.
Jensa C. Morris, MD, of the Yale School of Medicine, Smilow Hospitalist Service, discusses her findings on the benefits of hospitalist co-management of patients with cancer: It reduced the length of hospital stay by 1 day, increased early discharge (before 11:00 AM) by threefold; raised the educational rankings of house staff, and lowered oncologists’ stress level, improving their ability to manage competing responsibilities (Abstract 1).
Dawn L. Hershman, MD, of Columbia University College of Physicians and Surgeons, discusses findings that showed substantial variability in clinicians’ adherence to prescribing primary prophylactic colony stimulating factors in a pragmatic trial. Although the ability to opt out of the intervention is a feature of pragmatic trials, careful prestudy planning to estimate nonadherence is critical to ensure adequate power to detect an effect. Understanding reasons for intervention opt-outs may also inform future pragmatic studies aimed at improving adherence to practice guidelines.
Christopher E. Jensen, MD, of the University of North Carolina School of Medicine, talks about older adults with acute myeloid leukemia who receive high-intensity chemotherapy. Although they may live longer, much of their survival gains may be spent engaged in oncology care (Abstract 376).